Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combined oral hormone replacement therapy formulations.

J H Mattox1, L P Shulman

  • 1Department of Obstetrics and Gynecology, Good Samaritan Regional Medical Center, Phoenix, AZ 85006, USA.

American Journal of Obstetrics and Gynecology
|August 25, 2001
PubMed
Summary

Transitioning from oral contraceptives to hormone replacement therapy (HRT) requires careful progestin selection for optimal symptom relief and tolerability. New HRT formulations may offer improved benefits over older options.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESC expert statement on the effects on mood of the natural cycle and progestin-only contraceptives.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2017
Same author

Contraception for the perimenopausal woman.

Climacteric : the journal of the International Menopause Society·2016
Same author

Pharmacokinetics of 23-epi-26-deoxyactein in women after oral administration of a standardized extract of black cohosh.

Clinical pharmacology and therapeutics·2009
Same author

Androgens and menopause.

Minerva ginecologica·2009
Same author

Alternatives to oral regimens of contraception.

Minerva ginecologica·2007
Same author

[Late first-trimester invasive prenatal diagnosis--secondary publication. An international randomized trial].

Ugeskrift for laeger·2005

Area of Science:

  • Women's Health
  • Endocrinology
  • Pharmacology

Background:

  • Clinicians face challenges in managing women's contraceptive needs and transitioning them to menopausal hormone therapy.
  • Effective menopausal therapy requires symptom relief, noncontraceptive health benefits, and good tolerability.
  • Hormone replacement therapy (HRT) offers benefits like vasomotor symptom control, osteoporosis prevention, and potential protection against cardiovascular disease, colon cancer, and Alzheimer's disease.

Purpose of the Study:

  • To evaluate the transition from oral contraceptives to hormone replacement therapy.
  • To highlight the importance of progestin tolerability in HRT formulations.
  • To compare the potential advantages of new HRT formulations.

Main Methods:

  • Review of current hormone replacement therapy formulations available in the United States.

Related Experiment Videos

  • Analysis of available data on the tolerability profiles of different progestins used in HRT.
  • Consideration of the transition from oral contraceptive use to HRT.

    • Main Results:

    • Progestin-related side effects are a primary reason for HRT discontinuation.
    • Selecting an HRT formulation with a well-tolerated progestin, similar to that in oral contraceptives, can improve adherence.
    • Continuous 17beta-estradiol/intermittent norgestimate HRT may offer advantages over older progestin-containing regimens.

    Conclusions:

    • The choice of progestin in hormone replacement therapy is critical for patient adherence and successful treatment.
    • Newer HRT formulations, such as continuous 17beta-estradiol/intermittent norgestimate, show promise for improved tolerability and benefits.
    • Further comparative trials are needed to confirm the advantages of novel HRT formulations.